CompletedNCT01450514
Pipamperone Added to Ongoing Treatment for Schizophrenia
About this title
Read the official source — NCT01450514Medication studyAges 18–65Belgium
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- KortenbergSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMarch 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 7
- Sponsor
- PharmaNeuroBoost N.V.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Belgium
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01450514
- Official title
Show the full official title
POC Study of Pipamperone 15mg Added to Stable Risperidone or Paliperidone Treatment in Chronic Schizophrenic and Schizoaffective Patients With Residual Symptoms: a Phase I/IIa, Randomized, Double-blind, Placebo-controlled Trial of 7 Weeks
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Kortenberg
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is PharmaNeuroBoost N.V.
Did this study involve medication?
Yes. The study involved medication, including Pipamperone and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication